Information: Due to increasing bot activity we were unfortunately forced to place the search behind a login. Links to models can still be shared with others and viewed without a login. Thank you for your understanding.
Information:
Fel:
ID
30257
Beskrivning
Phase I Study of Ixabepilone Plus Lapatinib With or Without Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00634088
Länk
https://clinicaltrials.gov/show/NCT00634088
Nyckelord
Versioner (1)
- 2018-05-25 2018-05-25 -
Rättsinnehavare
See clinicaltrials.gov
Uppladdad den
25 maj 2018
DOI
För en begäran logga in.
Licens
Creative Commons BY 4.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Eligibility Locally Advanced or Metastatic Breast Cancer NCT00634088
Eligibility Locally Advanced or Metastatic Breast Cancer NCT00634088
- StudyEvent: Eligibility
Similar models
Eligibility Locally Advanced or Metastatic Breast Cancer NCT00634088
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
Gender | Age | Breast adenocarcinoma
Item
females aged 18 years or older with histologic or cytologic diagnosis of adenocarcinoma originating in the breast
boolean
C0079399 (UMLS CUI [1])
C0001779 (UMLS CUI [2])
C0858252 (UMLS CUI [3])
C0001779 (UMLS CUI [2])
C0858252 (UMLS CUI [3])
Neoplasm Metastasis TNM clinical staging | Locally Advanced Malignant Neoplasm TNM clinical staging | Incurable disease | Therapeutic radiology procedure Unsuccessful | Operative Surgical Procedures Unsuccessful
Item
radiologic or pathologic evidence that the cancer is metastatic or locally advanced (a t4 tumor and stage iiib/iiic disease) and not curable by local measures, such as radiation or surgery
boolean
C0027627 (UMLS CUI [1,1])
C3258246 (UMLS CUI [1,2])
C0677984 (UMLS CUI [2,1])
C3258246 (UMLS CUI [2,2])
C0175969 (UMLS CUI [3])
C1522449 (UMLS CUI [4,1])
C1272705 (UMLS CUI [4,2])
C0543467 (UMLS CUI [5,1])
C1272705 (UMLS CUI [5,2])
C3258246 (UMLS CUI [1,2])
C0677984 (UMLS CUI [2,1])
C3258246 (UMLS CUI [2,2])
C0175969 (UMLS CUI [3])
C1522449 (UMLS CUI [4,1])
C1272705 (UMLS CUI [4,2])
C0543467 (UMLS CUI [5,1])
C1272705 (UMLS CUI [5,2])
HER2/Neu Positive
Item
positive status for human epidermal growth factor receptor 2
boolean
C2348909 (UMLS CUI [1])
Measurable Disease
Item
measurable disease as per response evaluation criteria in solid tumors guidelines
boolean
C1513041 (UMLS CUI [1])
Karnofsky Performance Status
Item
karnofsky performance status of 70 to 100
boolean
C0206065 (UMLS CUI [1])
Life Expectancy
Item
life expectancy of at least 3 months
boolean
C0023671 (UMLS CUI [1])
Irradiation of pelvis Bone Marrow Percentage | Prior radiation therapy Lumbar spine Bone Marrow Percentage
Item
prior radiation must not have included 30% or more of major bone-marrow containing areas, such as the pelvis and lumbar spine
boolean
C0747411 (UMLS CUI [1,1])
C0005953 (UMLS CUI [1,2])
C0439165 (UMLS CUI [1,3])
C0279134 (UMLS CUI [2,1])
C0024091 (UMLS CUI [2,2])
C0005953 (UMLS CUI [2,3])
C0439165 (UMLS CUI [2,4])
C0005953 (UMLS CUI [1,2])
C0439165 (UMLS CUI [1,3])
C0279134 (UMLS CUI [2,1])
C0024091 (UMLS CUI [2,2])
C0005953 (UMLS CUI [2,3])
C0439165 (UMLS CUI [2,4])
Neuropathy CTCAE Grades
Item
common terminology criteria grade 2 or greater neuropathy
boolean
C0442874 (UMLS CUI [1,1])
C1516728 (UMLS CUI [1,2])
C1516728 (UMLS CUI [1,2])
Hematologic function | Liver function | Renal function
Item
inadequate hematologic, hepatic, or renal function
boolean
C0221130 (UMLS CUI [1])
C0232741 (UMLS CUI [2])
C0232804 (UMLS CUI [3])
C0232741 (UMLS CUI [2])
C0232804 (UMLS CUI [3])
Severe allergy Cremophor EL Pharmaceutical Preparations | Hypersensitivity Fluoropyrimidine | Intolerance to Fluoropyrimidine
Item
known prior severe hypersensitivity reactions to agents containing cremophor® el or known hypersensitivity or prior intolerance to fluoropyrimidine
boolean
C2945656 (UMLS CUI [1,1])
C0056476 (UMLS CUI [1,2])
C0013227 (UMLS CUI [1,3])
C0020517 (UMLS CUI [2,1])
C0596581 (UMLS CUI [2,2])
C1744706 (UMLS CUI [3,1])
C0596581 (UMLS CUI [3,2])
C0056476 (UMLS CUI [1,2])
C0013227 (UMLS CUI [1,3])
C0020517 (UMLS CUI [2,1])
C0596581 (UMLS CUI [2,2])
C1744706 (UMLS CUI [3,1])
C0596581 (UMLS CUI [3,2])
Dihydropyrimidine Dehydrogenase Deficiency | Dihydropyrimidine Dehydrogenase Deficiency Suspected
Item
known or suspected dihydropyrimidine dehydrogenase deficiency
boolean
C1959620 (UMLS CUI [1])
C1959620 (UMLS CUI [2,1])
C0750491 (UMLS CUI [2,2])
C1959620 (UMLS CUI [2,1])
C0750491 (UMLS CUI [2,2])
Chemotherapy Regimen Quantity Neoplasm Metastasis
Item
more than 3 prior chemotherapy regimens in the metastatic setting
boolean
C0392920 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C0027627 (UMLS CUI [1,3])
C1265611 (UMLS CUI [1,2])
C0027627 (UMLS CUI [1,3])
Epothilone | lapatinib | capecitabine
Item
prior treatment with an epothilone or lapatinib; prior treatment with capecitabine within the past 6 months
boolean
C1136012 (UMLS CUI [1])
C1506770 (UMLS CUI [2])
C0671970 (UMLS CUI [3])
C1506770 (UMLS CUI [2])
C0671970 (UMLS CUI [3])